These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33322952)

  • 1. Potential effectiveness and adverse implications of repurposing doxycycline in COVID-19 treatment.
    Narendrakumar L; Joseph I; Thomas S
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1001-1008. PubMed ID: 33322952
    [No Abstract]   [Full Text] [Related]  

  • 2. Repurposing of antibiotics for clinical management of COVID-19: a narrative review.
    Yacouba A; Olowo-Okere A; Yunusa I
    Ann Clin Microbiol Antimicrob; 2021 May; 20(1):37. PubMed ID: 34020659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combating COVID-19: The role of drug repurposing and medicinal plants.
    Khan SA; Al-Balushi K
    J Infect Public Health; 2021 Apr; 14(4):495-503. PubMed ID: 33743371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
    Norinder U; Tuck A; Norgren K; Munic Kos V
    Biomed Pharmacother; 2020 Oct; 130():110582. PubMed ID: 32763818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress.
    Hossain MJ; Rahman SMA
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1009-1027. PubMed ID: 33355520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxycycline as an Alternative to Azithromycin in Elderly Patients.
    Malek AE; Granwehr BP
    Int J Antimicrob Agents; 2021 Jan; 57(1):106168. PubMed ID: 33408018
    [No Abstract]   [Full Text] [Related]  

  • 7. A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics.
    Wattanakul T; Chotsiri P; Scandale I; Hoglund RM; Tarning J
    Expert Rev Clin Pharmacol; 2022 Aug; 15(8):945-958. PubMed ID: 36017624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilizing clinical pharmacology in the drug repurposing arena: a look into COVID-19.
    Ruggiero R; Balzano N; Di Napoli R; Sullo MG; Rossi F; Capuano A; Rafaniello C
    Expert Rev Clin Pharmacol; 2022 Oct; 15(10):1225-1231. PubMed ID: 36196903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications.
    Garrido-Mesa J; Adams K; Galvez J; Garrido-Mesa N
    Expert Opin Investig Drugs; 2022 May; 31(5):475-482. PubMed ID: 35294307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety perspectives on presently considered drugs for the treatment of COVID-19.
    Penman SL; Kiy RT; Jensen RL; Beoku-Betts C; Alfirevic A; Back D; Khoo SH; Owen A; Pirmohamed M; Park BK; Meng X; Goldring CE; Chadwick AE
    Br J Pharmacol; 2020 Oct; 177(19):4353-4374. PubMed ID: 32681537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic.
    Khadka S; Yuchi A; Shrestha DB; Budhathoki P; Al-Subari SMM; Ziad Alhouzani TM; Anwar Butt I
    Altern Ther Health Med; 2020 Aug; 26(S2):100-107. PubMed ID: 32827400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing drugs for the management of COVID-19.
    Cusinato J; Cau Y; Calvani AM; Mori M
    Expert Opin Ther Pat; 2021 Apr; 31(4):295-307. PubMed ID: 33283567
    [No Abstract]   [Full Text] [Related]  

  • 13. A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID-19.
    Martin JH; Head R
    Br J Clin Pharmacol; 2021 Mar; 87(3):875-885. PubMed ID: 32959913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progress in the repurposing of drugs/molecules for the management of COVID-19.
    Sharma D; Kunamneni A
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):889-897. PubMed ID: 33270490
    [No Abstract]   [Full Text] [Related]  

  • 15. Can drug repurposing strategies be the solution to the COVID-19 crisis?
    Bellera CL; Llanos M; Gantner ME; Rodriguez S; Gavernet L; Comini M; Talevi A
    Expert Opin Drug Discov; 2021 Jun; 16(6):605-612. PubMed ID: 33345645
    [No Abstract]   [Full Text] [Related]  

  • 16. An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic.
    Paula HSC; Santiago SB; Araújo LA; Pedroso CF; Marinho TA; Gonçalves IAJ; Santos TAP; Pinheiro RS; Oliveira GA; Batista KA
    Braz J Med Biol Res; 2021; 55():e11631. PubMed ID: 34909910
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19.
    Aldea M; Michot JM; Danlos FX; Ribas A; Soria JC
    Cancer Discov; 2021 Jun; 11(6):1336-1344. PubMed ID: 33846172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19: Potential Repurposing Drugs.
    Leowattana W
    Infect Disord Drug Targets; 2022; 22(1):e110122191924. PubMed ID: 33645490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.